Dyax Corp. (DYAX)
-NasdaqGM 2.53 
0.01(0.40%) 4:00PM EDT|After Hours
:
2.53 0.00 (0.00%) 4:31PM EDT
| Prev Close: | 2.52 |
|---|
| Open: | 2.53 |
|---|
| Bid: | 1.56 x 100 |
|---|
| Ask: | 4.99 x 200 |
|---|
| 1y Target Est: | 4.67 |
|---|
| Beta: | 1.04 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.48 - 2.58 |
|---|
| 52wk Range: | 1.54 - 4.50 |
|---|
| Volume: | 439,316 |
|---|
| Avg Vol (3m): | 685,038 |
|---|
| Market Cap: | 253.64M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.29 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Dyax HAE Allies℠ Awards Program Launches on Second Annual Hereditary Angioedema (HAE) Day – a Global Event to Raise Awareness of HAEBusiness Wire(Thu, May 16)
- DYAX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; CEDGAR Online(Wed, May 15)
- DYAX CORP Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Wed, May 15)
- Dyax Announces $30 Million OfferingBusiness Wire(Mon, May 13)
- DYAX CORP FinancialsEDGAR Online Financials(Fri, May 10)
- Despite Poor Quarter, ViroPharma's Commercial And Pipeline Progress Continueat Seeking Alpha(Fri, May 3)
- DYAX CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 2)
- 3 Biggest Biotech Crashes in Aprilat Motley Fool(Thu, May 2)
- Dyax Corp. to Participate in the Needham Healthcare ConferenceBusiness Wire(Mon, Apr 29)
- 5 of Last Week's Biggest Losersat Motley Fool(Sun, Apr 28)
- The Best- And Worst-Performing Biotech Stocks, April 19 to April 26at Forbes(Sat, Apr 27)
- 3 Horrendous Health-Care Stocks This Weekat Motley Fool(Sat, Apr 27)
- Why Shares of Dyax Dropped Like a Rockat Motley Fool(Fri, Apr 26)
- Dyax Corporation's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, Apr 25)
- Dyax Corp. Announces First Quarter 2013 Financial ResultsBusiness Wire(Thu, Apr 25)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 4.58 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.27 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.06 |
|---|
| Mean Recommendation*: | 1.3 |
|---|
| PEG Ratio (5 yr expected): | -2.33 |
|---|
Business Summary
Dyax Corp., a biopharmaceutical company, engages in the identification, development, and commercialization of treatments for plasma kallikrein-mediated (PKM) angioedemas.
View More